Nucleai, a company leveraging AI-powered spatial biology to tackle challenges in precision medicine, has secured $14.0M in new investment. Its Atom platform, described as a leading spatial biology platform, is licensed to major pharmaceutical companies for internal research and used in collaborations for biomarker discovery projects.
The company's core mission is to improve drug development, clinical treatment decisions, and patient outcomes. This latest capital infusion will support Nucleai's ongoing efforts to bring advanced analytics to the forefront of medical research, enhancing the discovery of critical biomarkers.














